About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington’s Disease Research

By: via Business Wire

Charles River Laboratories International, Inc. (NYSE: CRL) and CHDI Foundation, Inc., today announced an extension of their ongoing drug discovery partnership into the foreseeable future. The organizations began working together in 2005 to expedite therapeutic development for Huntington’s disease (HD), a genetic neurological disorder that causes the progressive dysfunction of nerve cells in the brain. The extension in 2025, marking the 20-year anniversary of the collaboration, will allow more flexible activity across Charles River’s global network of scientific expertise and provide greater integration into CHDI’s programs.

“For two decades, we’ve been proud to be close partners of CHDI,” said Shannon M. Parisotto, Corporate Executive Vice President, Global Discovery & Safety Assessment, Charles River. “They are doing incredible work, tirelessly exploring and progressing options for the treatment of Huntington’s disease. We are excited for the future of research and working collaboratively to bring therapeutics to the families impacted by this disease.”

The contract extension covers multidisciplinary services from across Charles River’s portfolio, including:

  • Integrated chemistry, biology, and absorption, distribution, metabolism, and excretion (ADME) for small molecule drug discovery
  • Stem cell and iPSC-derived neuronal assay development and screening
  • High-throughput screening (HTS), high-content and fragment-based screening
  • Computational chemistry and drug design
  • ADME and pharmacokinetics (PK)
  • Protein crystallography and biophysics
  • Extensive in vivo pharmacology in HD research models for translational assessment
  • Safety pharmacology
  • Biomarker discovery and assessment
  • (Chemo)Proteomics
  • Viral production

Over their 20-year collaboration, Charles River has established and validated tools and methodologies within expert teams to support CHDI’s mission of collaboratively developing therapeutics that will substantially improve the lives of those affected by the disease.

“The Charles River team have become true scientific colleagues, and we highly value the intellectual and technical contributions that they have made across dozens of projects over the course of our two-decade collaboration,” said Robert Pacifici, Ph.D., Chief Scientific Officer, CHDI. “We look forward to further deepening our research collaboration to bring benefit to Huntington’s families as soon as we can.”

Together, Charles River and CHDI have worked on novel potential drug targets, engineered and validated translational research animal models, run large HTS campaigns, generated proof-of-concept molecules, and evaluated the potential efficacy of both small molecule and biologic therapeutic candidates in preclinical models of HD. These cutting-edge approaches have resulted in 15 composition of matter patent applications.

“We have a wonderful global team of highly skilled and knowledgeable scientists who are closely integrated with CHDI’s team,” added David Fischer, Ph.D., Chief Technology Officer, Discovery, Charles River. “We all recognize the critical need for effective treatments for HD and until that is a reality, we will continue pushing research forward.”

Additionally, the expertise and assets developed throughout this collaboration have facilitated research within the broader HD drug discovery and development community, which today includes more than 50 pharma and biotech companies.

CHDI has also agreed to share data with Charles River’s learning algorithms, helping to power and inform the industry's largest and most diverse dataset. Charles River is passionate about protecting data, using industry-standard platforms for data sharing, and irreversible data processing methods. Because Charles River’s data models exclude models used for target identification, on-target activity and efficacy profiles related to the target, clients can be assured that their data is used responsibly.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

About CHDI Foundation, Inc.

CHDI Foundation, Inc. is a privately-funded nonprofit biomedical research organization that is exclusively dedicated to collaboratively developing therapeutics that will substantially improve the lives of those affected by Huntington’s disease. As a collaborative enabler, CHDI seeks to bring the right partners together to identify and address critical scientific issues and move drug candidates to clinical evaluation as quickly as possible. Our scientists work closely with a network of more than 700 researchers in academic and industrial laboratories around the world in the pursuit of these novel therapies, providing strategic scientific direction to ensure that our common goals remain in focus. More information about CHDI can be found at www.chdifoundation.org.

“The Charles River team have become true scientific colleagues, and we highly value the intellectual and technical contributions that they have made across dozens of projects over the course of our two-decade collaboration."

Contacts

Investor Contact:



Charles River

Todd Spencer

Corporate Vice President, Investor Relations

781-222-6455

todd.spencer@crl.com



Media Contacts:



Charles River

Amy Cianciaruso

Corporate Vice President, Public Relations

781-222-6168

amy.cianciaruso@crl.com

More News

View More
Salesforce’s Long-Awaited Inflection is Here: Rally On!
Via MarketBeat
Topics Artificial Intelligence
Tickers CRM GOOGL
Rocket Lab USA Receives Wall Street Validation: Time to Buy?
Via MarketBeat
Tickers MS RKLB
Archer Buys Rival's Patent Treasure Trove in Strategic Move
Via MarketBeat
Topics Intellectual Property
Tickers ACHR
What Amazon's Chart Says a Week Before Earnings
Via MarketBeat
Tickers AMZN
Smart Money's Big Bet on AST SpaceMobile
Via MarketBeat
Tickers AMT ASTS BCE BLK RKUNY T
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.